Literature DB >> 20080612

Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor.

Jianxiong Jiang1, Thota Ganesh, Yuhong Du, Pahk Thepchatri, Asheebo Rojas, Iestyn Lewis, Serdar Kurtkaya, Lian Li, Min Qui, Geidy Serrano, Renee Shaw, Aiming Sun, Ray Dingledine.   

Abstract

Activation of the Galphas-coupled EP2 receptor for prostaglandin E2 (PGE(2)) promotes cell survival in several models of tissue damage. To advance understanding of EP2 functions, we designed experiments to develop allosteric potentiators of this key prostaglandin receptor. Screens of 292,000 compounds identified 93 that at 20 microM (i) potentiated the cAMP response to a low concentration of PGE(2) by > 50%; (ii) had no effect on EP4 or beta2 adrenergic receptors, the cAMP assay itself, or the parent cell line; and (iii) increased the potency of PGE(2) on EP2 receptors at least 3-fold. In aqueous solution, the active compounds are largely present as nanoparticles that appear to serve as active reservoirs for bioactive monomer. From 94 compounds synthesized or purchased, based on the modification of one hit compound, the most active increased the potency of PGE(2) on EP2 receptors 4- to 5-fold at 10 to 20 microM and showed substantial neuroprotection in an excitotoxicity model. These small molecules represent previously undescribed allosteric modulators of a PGE(2) receptor. Our results strongly reinforce the notion that activation of EP2 receptors by endogenous PGE(2) released in a cell-injury setting is neuroprotective.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20080612      PMCID: PMC2836658          DOI: 10.1073/pnas.0909310107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

Review 1.  Prostanoid receptors: subtypes and signaling.

Authors:  R M Breyer; C K Bagdassarian; S A Myers; M D Breyer
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

2.  LeadScope: data visualization for large volumes of chemical and biological screening data.

Authors:  A Richon
Journal:  J Mol Graph Model       Date:  2000-02       Impact factor: 2.518

3.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.

Authors:  Susan L McGovern; Emilia Caselli; Nikolaus Grigorieff; Brian K Shoichet
Journal:  J Med Chem       Date:  2002-04-11       Impact factor: 7.446

4.  NMDA receptor-mediated excitotoxic neuronal apoptosis in vitro and in vivo occurs in an ER stress and PUMA independent manner.

Authors:  Caoimhín G Concannon; Manus W Ward; Helena P Bonner; Katsura Kuroki; Liam P Tuffy; Caroline T Bonner; Ina Woods; Tobias Engel; David C Henshall; Jochen H M Prehn
Journal:  J Neurochem       Date:  2007-12-13       Impact factor: 5.372

5.  Altered hippocampal long-term synaptic plasticity in mice deficient in the PGE2 EP2 receptor.

Authors:  Hongwei Yang; Jian Zhang; Richard M Breyer; Chu Chen
Journal:  J Neurochem       Date:  2008-11-21       Impact factor: 5.372

6.  Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors.

Authors:  Kristin E D Coan; Brian K Shoichet
Journal:  J Am Chem Soc       Date:  2008-06-28       Impact factor: 15.419

7.  Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice.

Authors:  C Iadecola; K Niwa; S Nogawa; X Zhao; M Nagayama; E Araki; S Morham; M E Ross
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

8.  The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis.

Authors:  Xibin Liang; Qian Wang; Ju Shi; Ludmila Lokteva; Richard M Breyer; Thomas J Montine; Katrin Andreasson
Journal:  Ann Neurol       Date:  2008-09       Impact factor: 10.422

Review 9.  Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders.

Authors:  P Jeffrey Conn; Arthur Christopoulos; Craig W Lindsley
Journal:  Nat Rev Drug Discov       Date:  2009-01       Impact factor: 84.694

10.  Microglial inhibition of neuroprotection by antagonists of the EP1 prostaglandin E2 receptor.

Authors:  Noel G Carlson; Monica A Rojas; John-David Black; Jonathan W Redd; John Hille; Kenneth E Hill; John W Rose
Journal:  J Neuroinflammation       Date:  2009-02-17       Impact factor: 8.322

View more
  49 in total

Review 1.  Defining the therapeutic time window for suppressing the inflammatory prostaglandin E2 signaling after status epilepticus.

Authors:  Yifeng Du; Timothy Kemper; Jiange Qiu; Jianxiong Jiang
Journal:  Expert Rev Neurother       Date:  2016-01-13       Impact factor: 4.618

2.  Applying label-free dynamic mass redistribution technology to frame signaling of G protein-coupled receptors noninvasively in living cells.

Authors:  Ralf Schröder; Johannes Schmidt; Stefanie Blättermann; Lucas Peters; Nicole Janssen; Manuel Grundmann; Wiebke Seemann; Dorina Kaufel; Nicole Merten; Christel Drewke; Jesus Gomeza; Graeme Milligan; Klaus Mohr; Evi Kostenis
Journal:  Nat Protoc       Date:  2011-10-20       Impact factor: 13.491

3.  Ablation of cyclooxygenase-2 in forebrain neurons is neuroprotective and dampens brain inflammation after status epilepticus.

Authors:  G E Serrano; N Lelutiu; A Rojas; S Cochi; R Shaw; C D Makinson; D Wang; G A FitzGerald; R Dingledine
Journal:  J Neurosci       Date:  2011-10-19       Impact factor: 6.167

4.  Small-molecule inhibition of prostaglandin E receptor 2 impairs cyclooxygenase-associated malignant glioma growth.

Authors:  Jiange Qiu; Qianqian Li; Katherine A Bell; Xue Yao; Yifeng Du; Erik Zhang; Jane J Yu; Ying Yu; Zhi Shi; Jianxiong Jiang
Journal:  Br J Pharmacol       Date:  2019-04-29       Impact factor: 8.739

5.  Suppressing pro-inflammatory prostaglandin signaling attenuates excitotoxicity-associated neuronal inflammation and injury.

Authors:  Jianxiong Jiang; Ying Yu; Erika Reime Kinjo; Yifeng Du; Hoang Phuong Nguyen; Ray Dingledine
Journal:  Neuropharmacology       Date:  2019-02-11       Impact factor: 5.250

6.  Internal Structure and Preferential Protein Binding of Colloidal Aggregates.

Authors:  Da Duan; Hayarpi Torosyan; Daniel Elnatan; Christopher K McLaughlin; Jennifer Logie; Molly S Shoichet; David A Agard; Brian K Shoichet
Journal:  ACS Chem Biol       Date:  2016-12-16       Impact factor: 5.100

Review 7.  Cyclooxygenase-2 in glioblastoma multiforme.

Authors:  Jiange Qiu; Zhi Shi; Jianxiong Jiang
Journal:  Drug Discov Today       Date:  2016-09-28       Impact factor: 7.851

8.  Assessment of the in vitro toxicity of calixarenes and a metal-seamed calixarene: a chemical pathway for clinical application.

Authors:  Arnab Dawn; Xue Yao; Ying Yu; Jianxiong Jiang; Harshita Kumari
Journal:  Supramol Chem       Date:  2019-05-13       Impact factor: 1.688

9.  Development of second generation EP2 antagonists with high selectivity.

Authors:  Thota Ganesh; Jianxiong Jiang; Ray Dingledine
Journal:  Eur J Med Chem       Date:  2014-06-03       Impact factor: 6.514

10.  Activation of group I metabotropic glutamate receptors potentiates heteromeric kainate receptors.

Authors:  Asheebo Rojas; Jonathon Wetherington; Renee Shaw; Geidy Serrano; Sharon Swanger; Raymond Dingledine
Journal:  Mol Pharmacol       Date:  2012-10-11       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.